Egetis Therapeutics AB (publ) (STO:EGTX)

Market Cap	1.32B
Revenue (ttm)	46.70M
Net Income (ttm)	-331.50M
Shares Out	359.24M
EPS (ttm)	-1.03
PE Ratio	n/a
Forward PE	5.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	476,032
Average Volume	412,984
Open	3.620
Previous Close	3.555
Day's Range	3.600 - 3.705
52-Week Range	3.315 - 9.300
Beta	1.08
RSI	44.12
Earnings Date	Apr 30, 2025

About Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 40
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: EGTX

Financial Performance

In 2024, Egetis Therapeutics AB's revenue was 46.10 million, a decrease of -19.97% compared to the previous year's 57.60 million. Losses were -343.60 million, 5.11% more than in 2023.